Reata Pharmaceuticals, Inc (RETA)

Etorro trading 970x250
Reata Pharmaceuticals, Inc (RETA) Logo

About Reata Pharmaceuticals, Inc

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich’s ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Address: 5320 Legacy Drive, Plano, TX, United States, 75024

Reata Pharmaceuticals, Inc News and around…

Latest news about Reata Pharmaceuticals, Inc (RETA) common stock and company :

Do Options Traders Know Something About Reata (RETA) Stock We Don't?
01 Dec, 2021 Yahoo! Finance

Investors need to pay close attention to Reata (RETA) stock based on the movements in the options market lately.

Notable Monday Option Activity: RSI, RETA, ZM
29 Nov, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Rush Street Interactive Inc Class A (RSI), where a total of 29,673 contracts have traded so far, representing approximately 3.0 million underlying shares. That amounts to about 231.4% of RSI's average daily trading volume over the past month of 1.3 million shares..

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
19 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic ...

Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
19 Nov, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich’s ataxia.

Noteworthy Wednesday Option Activity: RETA, SIGA, CTRN
17 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Reata Pharmaceuticals Inc (RETA), where a total volume of 3,755 contracts has been traded thus far today, a contract volume which is representative of approximately 375,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 160.1% of RETA's average daily trading volume over the past month, of 234,515 shares..

Notable Tuesday Option Activity: BHVN, RETA, MSP
09 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biohaven Pharmaceutical Holding Co Ltd (BHVN), where a total volume of 2,970 contracts has been traded thus far today, a contract volume which is representative of approximately 297,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 104.8% of BHVN's average daily trading volume over the past month, of 283,345 shares..

Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat
09 Nov, 2021 Yahoo! Finance

Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.

Reata Pharmaceuticals, inc (RETA) Q3 2021 Earnings Call Transcript
08 Nov, 2021 FinancialContent

RETA earnings call for the period ending September 30, 2021.

Reata Pharmaceuticals's Return On Capital Employed Overview
08 Nov, 2021 FinancialContent

According to Benzinga Pro data, during Q3, Reata Pharmaceuticals (NASDAQ:RETA) posted sales of $7.39 million. Earnings were up 3.38%, ...

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates
08 Nov, 2021 Yahoo! Finance

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 15.09% and 427.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals: Q3 Earnings Insights
08 Nov, 2021 FinancialContent

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q3 earnings results on Monday, November 8, 2021 at 08:00 AM. Here's ...

Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
08 Nov, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2021, and provided an update on the Company’s business operations and clinical development programs.

Earnings Scheduled For November 8, 2021
08 Nov, 2021 FinancialContent

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 ...

A Preview Of Reata Pharmaceuticals's Earnings
05 Nov, 2021 FinancialContent

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors ...

Reata Pharmaceuticals (NASDAQ:RETA) Is In A Good Position To Deliver On Growth Plans
02 Nov, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline
01 Nov, 2021 Yahoo! Finance

Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021
01 Nov, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs pre-market on November 8, 2021.

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
29 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study ...

Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
28 Oct, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced its submission of a Marketing Authorization Application (“MAA”) for bardoxolone methyl (“bardoxolone”) to the European Medicines Agency (“EMA”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.

Noteworthy Tuesday Option Activity: WGO, RETA, DE
26 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Winnebago Industries, Inc. (WGO), where a total volume of 3,997 contracts has been traded thus far today, a contract volume which is representative of approximately 399,700 underlying shares (given that every 1 contract represents 100 underlying shares)..

Reata Pharmaceuticals Announces Presentations at the American Society of Nephrology Kidney Week 2021
15 Oct, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held virtually from November 4 – 7, 2021.

Reata Pharmaceuticals Announces Presentations at the American Society of Nephrology Kidney Week 2021
15 Oct, 2021 Yahoo! Finance

PLANO, Texas, October 15, 2021--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," or "we"), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for bardoxolone methyl ("bardoxolone") and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held virtually from November 4 – 7, 2021.

Notable Friday Option Activity: RETA, CWEN, TKR
01 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Reata Pharmaceuticals Inc (RETA), where a total volume of 874 contracts has been traded thus far today, a contract volume which is representative of approximately 87,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53.6% of RETA's average daily trading volume over the past month, of 163,045 shares..

Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022
01 Oct, 2021 Yahoo! Finance

Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.

How The Parts Add Up: VB Targets $259
01 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap ETF (VB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $259.08 per unit.

Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
30 Sep, 2021 FinancialContent

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has completed its pre-New Drug Application (“NDA”) meeting with the United States Food and Drug Administration (“FDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia and reaffirmed its plan to submit an NDA in the first quarter of 2022.

Notable Tuesday Option Activity: UBER, RETA, WWD
21 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Uber Technologies Inc (UBER), where a total volume of 838,371 contracts has been traded thus far today, a contract volume which is representative of approximately 83.8 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 331.7% of UBER's average daily trading volume over the past month, of 25.3 million shares..

2 Biotech Stocks to Buy Right Now
19 Sep, 2021 FinancialContent

They both have great growth prospects.

Reata Pharmaceuticals's Return on Invested Capital Overview
17 Sep, 2021 FinancialContent

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, ...

Reata Pharmaceuticals, Inc (RETA) is a NASDAQ Common Stock listed in , ,

970x250